These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34564675)

  • 21. Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.
    Miethe S; Rasetti-Escargueil C; Avril A; Liu Y; Chahboun S; Korkeala H; Mazuet C; Popoff MR; Pelat T; Thullier P; Sesardic D; Hust M
    PLoS One; 2015; 10(10):e0139905. PubMed ID: 26440796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations.
    Diamant E; Lachmi BE; Keren A; Barnea A; Marcus H; Cohen S; David AB; Zichel R
    PLoS One; 2014; 9(1):e87089. PubMed ID: 24475231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RBC Adherence of Immune Complexes Containing Botulinum Toxin Improves Neutralization and Macrophage Uptake.
    Al-Saleem FH; Sharma R; Puligedda RD; Elias M; Kattala CD; Simon PM; Simpson LL; Dessain SK
    Toxins (Basel); 2017 May; 9(5):. PubMed ID: 28534855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
    Yang GH; Kim KS; Kim HW; Jeong ST; Huh GH; Kim JC; Jung HH
    Toxicon; 2004 Jul; 44(1):19-25. PubMed ID: 15225558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A human bispecific antibody neutralizes botulinum neurotoxin serotype A.
    Lu J; Jiang Y; Guo J; Chen L; Liu F; Li Z; Liu X; Du P; Yu Y; Wang R; Yang Z
    Sci Rep; 2023 Nov; 13(1):20806. PubMed ID: 38012220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.
    Rasetti-Escargueil C; Avril A; Chahboun S; Tierney R; Bak N; Miethe S; Mazuet C; Popoff MR; Thullier P; Hust M; Pelat T; Sesardic D
    MAbs; 2015; 7(6):1161-77. PubMed ID: 26381852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1.
    Sanford DC; Barnewall RE; Vassar ML; Niemuth N; Metcalfe K; House RV; Henderson I; Shearer JD
    Clin Vaccine Immunol; 2010 Sep; 17(9):1293-304. PubMed ID: 20660138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.
    You Z; Yang H; Xin W; Kang L; Gao S; Wang J; Zhang T; Wang J
    Hum Vaccin Immunother; 2014; 10(8):2321-7. PubMed ID: 25424938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin.
    Matsumura T; Kitamura M; Amatsu S; Yamaguchi A; Kobayashi N; Yutani M; Fujinaga Y
    Microbiol Immunol; 2024 Oct; 68(10):348-358. PubMed ID: 39239735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
    Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
    Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain.
    Chen C; Wang S; Wang H; Mao X; Zhang T; Ji G; Shi X; Xia T; Lu W; Zhang D; Dai J; Guo Y
    PLoS One; 2012; 7(8):e43845. PubMed ID: 22952786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production and characterization of a neutralizing antibody against botulinum neurotoxin A.
    Xiong X; Lv S; Fu C; Li L; Sun Z; Han X; Zhang W
    J Immunol Methods; 2020 Dec; 487():112871. PubMed ID: 33007319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B.
    Zhou H; Zhou B; Pellett S; Johnson EA; Janda KD
    Bioorg Med Chem Lett; 2009 Feb; 19(3):662-4. PubMed ID: 19112017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents.
    Sepulveda J; Mukherjee J; Tzipori S; Simpson LL; Shoemaker CB
    Infect Immun; 2010 Feb; 78(2):756-63. PubMed ID: 19917718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
    Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
    PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of botulinum neurotoxin serotype B at sub mouse LD(50) levels by a sandwich immunoassay and its application to toxin detection in milk.
    Scotcher MC; Cheng LW; Stanker LH
    PLoS One; 2010 Jun; 5(6):e11047. PubMed ID: 20548779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new neutralizing antibody against botulinum neurotoxin B recognizes the protein receptor binding sites for synaptotagmins II.
    Wang H; Li T; Shi J; Cai K; Hou X; Wang Q; Xiao L; Tu W; Liu H; Gao X
    Microbes Infect; 2010 Nov; 12(12-13):1012-8. PubMed ID: 20650331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.
    Avril A; Miethe S; Popoff MR; Mazuet C; Chahboun S; Rasetti-Escargueil C; Sesardic D; Thullier P; Hust M; Pelat T
    BMC Biotechnol; 2015 Sep; 15():86. PubMed ID: 26382731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
    J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.